^
Association details:
| Biomarker: | FGFR2-BICC1 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma
Excerpt:
...a 43 year old man who presented with a 7 cm ICC...SFA testing revealed a fusion between FGFR2 exon 17 and BICC1 exon 3. The patient enrolled in the BGJ398 trial and achieved a response of -28.4% at 2 months and a maximum response of -36.9% at 6 months.
DOI:
https://dx.doi.org/10.1158%2F2159-8290.CD-16-1000
